2
Clinical Trials associated with SCT-C21A Phase I Clinical Study Evaluating the Safety and Efficacy of SCTC21C in Participants With CD38+ Hematologic Malignancies
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
一项评价SCTC21C在CD38+血液瘤受试者中的安全性和有效性的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety and efficacy of SCTC21C in subjects with CD38+ hematological malignancies
主要目的:评价SCTC21C在复发/难治的CD38+血液瘤受试者中的耐受性和安全性,探索最大耐受剂量(MTD)和II期推荐剂量(RP2D)
次要目的:评价SCTC21C在复发/难治的CD38+血液瘤受试者中的初步有效性;评价SCTC21C在复发/难治的CD38+血液瘤受试者中的药代动力学(PK)特征;评价SCTC21C在复发/难治的CD38+血液瘤受试者中的药效动力学(PD)特征;评价SCTC21C在复发/难治的CD38+血液瘤受试者中的免疫原性
[Translation] Primary purpose: To evaluate the tolerability and safety of SCTC21C in subjects with relapsed/refractory CD38+ hematological tumors, and to explore the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D)
Secondary purpose: To evaluate the preliminary efficacy of SCTC21C in subjects with relapsed/refractory CD38+ hematological tumors; To evaluate the pharmacokinetic (PK) characteristics of SCTC21C in subjects with relapsed/refractory CD38+ hematological tumors; To evaluate the pharmacodynamic (PD) characteristics of SCTC21C in subjects with relapsed/refractory CD38+ hematological tumors; To evaluate the immunogenicity of SCTC21C in subjects with relapsed/refractory CD38+ hematological tumors
100 Clinical Results associated with SCT-C21
100 Translational Medicine associated with SCT-C21
100 Patents (Medical) associated with SCT-C21
100 Deals associated with SCT-C21